Core Insights - BioAge Labs, Inc. has reported positive interim Phase 1 data for BGE-102, a novel NLRP3 inhibitor, indicating potential best-in-class reductions in inflammatory biomarkers related to cardiovascular risk [1][2] - The company plans to initiate a Phase 2a proof-of-concept trial for BGE-102 in cardiovascular risk in the first half of 2026 and has expanded its indication into ophthalmology with a trial for diabetic macular edema planned for mid-2026 [1][5] Business Highlights - The Phase 1 trial of BGE-102 demonstrated well-tolerated results with significant pharmacokinetics supporting once-daily dosing, achieving 90-98% suppression of IL-1β and cerebrospinal fluid concentrations exceeding the IC90 at doses of 60 mg and above [5] - In the first MAD cohort, BGE-102 120 mg once daily achieved an 86% median reduction in hsCRP, with 93% of participants reaching levels below 2 mg/L, indicating reduced cardiovascular risk [5] - The company completed an upsized follow-on public offering generating total gross proceeds of approximately $132.3 million, which will support its expanding clinical programs [1][8] Financial Results - For the year ended December 31, 2025, collaboration revenue was $9.0 million, a significant increase from no revenue in 2024, attributed to a multi-year research collaboration with Novartis [10] - Research and development expenses rose to approximately $73.9 million in 2025 from $59.0 million in 2024, primarily due to increased costs related to various programs including BGE-102 [11] - The net loss for the year was $80.6 million, or $2.24 per share, compared to a net loss of $71.1 million, or $6.63 per share, in 2024 [15]

Core Viewpoint - BioAge Labs, Inc. announced a proposed underwritten public offering to sell up to $75 million of its common stock, with an additional option for underwriters to purchase up to $11.25 million more, aimed at funding various corporate activities [1][3]. Group 1: Offering Details - The proposed offering is subject to market conditions and there is no assurance regarding its completion or terms [1]. - Goldman Sachs & Co. LLC, Piper Sandler, and Citigroup are acting as joint book-running managers for the offering [2]. - The shares are being offered under a registration statement that became effective on November 25, 2025 [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for research, clinical development, manufacturing of product candidates, working capital, capital expenditures, and reduction of indebtedness [3]. Group 3: Company Overview - BioAge is a clinical-stage biopharmaceutical company focused on developing therapeutic candidates for metabolic diseases by targeting human aging biology [6]. - The lead product candidate, BGE-102, is a small-molecule NLRP3 inhibitor for cardiovascular risk and retinal diseases, with a Phase 1 trial currently underway [6].